Accordingly, prior literature in gastric cancer29 and in breast cancer with trastuzumab30 or trastuzumab deruxtecan31 support a positive correlation between HER2 gene copy number and response to anti-HER2 therapy. Here, ERBB2 is linked to breast cancer.